G6PD Testing: Performance and Interpretation
G6PD testing must be performed before primaquine administration using either quantitative spectrophotometric assays (gold standard) or point-of-care qualitative tests, with results interpreted as normal (≥70% activity), intermediate (30-<70% activity), or deficient (<30% activity) to guide primaquine dosing and prevent potentially fatal hemolysis 1.
How the Test is Performed
Testing Methods
Quantitative Testing (Gold Standard)
- Spectrophotometric enzyme activity assay measuring G6PD activity in U/g hemoglobin
- Provides precise enzyme activity levels
- Results expressed as percentage of normal activity (adjusted for local population norms)
Point-of-Care Qualitative Tests
CareStart G6PD test: Rapid qualitative screening showing normal vs. deficient status
Fluorescent Spot Test (FST): Detects G6PD enzyme activity through fluorescence
Timing Considerations
Critical timing issue: G6PD activity can be falsely elevated during acute malaria due to hemolysis-induced reticulocytosis 4, 5. However:
- Recent data from French Guiana shows G6PD activity remains stable from day 1 through day 28 in P. vivax patients 6
- No patients with normal G6PD activity at days 1-3 were reclassified as deficient at day 14 6
- Testing can be performed at presentation (day 1) rather than waiting until day 14, allowing earlier radical cure 6
Interpretation of Results
Classification System
Severe Deficiency (<30% activity)
- Primaquine is contraindicated in severe deficiency (<10% activity) 1
- For 10-30% activity: Use weekly primaquine 0.75 mg/kg for 8 weeks (PQ8W) 7, 8
Intermediate Deficiency (30-<70% activity)
- Can receive PQ8W regimen (0.75 mg/kg weekly × 8 weeks) 7
- Alternative: Daily primaquine with close monitoring 1
- Risk of hemolysis exists but manageable with monitoring 9
Normal (≥70% activity)
Special Populations
Heterozygous Females
- Present diagnostic challenge due to X-chromosome mosaicism
- May have >50% G6PD-deficient cells but test as normal phenotypically 10
- One heterozygous female was misclassified as normal by FST in real-world implementation 4
- Require particularly careful monitoring if primaquine is prescribed
Your Patient Context (Platelet Count 80,000/mm³)
- Thrombocytopenia does not contraindicate G6PD testing
- Proceed with G6PD testing before primaquine
- The low platelet count is typical of acute vivax malaria and should not delay testing
Critical Safety Monitoring
Mandatory Pre-Treatment Requirements 1
- Baseline hematocrit and hemoglobin must be checked before treatment
- Close hematological monitoring required at days 3 and 8
- Adequate medical support to manage hemolytic risk must be available
Warning Signs of Hemolysis 1
- Darkening of urine
- Marked fall in hemoglobin or erythrocyte count
- Discontinue primaquine immediately if these occur
Common Pitfalls
False normal results during acute malaria: While older literature suggested concern, recent prospective data shows this is not clinically significant in most cases 4, 6
Low specificity of qualitative tests: CareStart test showed only 68.1% specificity in Brazilian implementation, leading to unnecessary withholding of radical cure 3
Heterozygous females: Most challenging population to diagnose accurately; consider genotyping if available 10
Geographic variation in G6PD variants: Different variants (Viangchan, Mediterranean, Canton, etc.) have varying severity; Southeast Asian variants may tolerate higher doses 11, 8
Practical Algorithm for Your Patient
- Perform G6PD testing immediately (day 1) using available method (quantitative preferred, qualitative acceptable)
- Check baseline hemoglobin/hematocrit before any primaquine
- Interpret results:
- If ≥70%: Standard 14-day primaquine (0.5 mg/kg/day)
- If 30-<70%: Weekly primaquine 0.75 mg/kg × 8 weeks
- If <30%: Weekly primaquine 0.75 mg/kg × 8 weeks with enhanced monitoring
- If <10%: Primaquine contraindicated
- Monitor hemoglobin on days 3 and 8 regardless of G6PD status 1
- Ensure medical support available for potential hemolysis management
The FDA label explicitly requires G6PD testing before primaquine use, with residual risk of hemolysis acknowledged even after testing 1. The 2024 European guidelines support this approach while noting that weekly primaquine regimens provide safer alternatives for G6PD-deficient patients 7.